ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Argen X SE

Argen X SE (ARGX)

604,60
4,80
(0,80%)
Fermé 21 Décembre 5:30PM

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
604,60
Prix Achat
587,00
Prix Vente
610,00
Volume échangé
169 990
586,40 Fourchette du Jour 606,40
271,00 Plage de 52 semaines 613,00
Cap du marché
Clôture Veille
599,80
Ouverture
597,80
Dernière Transaction
100
@
604.6
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
58 304
Actions en circulation
59 194 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-121,30
Bénéfice par action (BPA)
-4,98
Chiffre d'affairess
1,27B
Bénéfice net
-295,05M

À propos de Argen X SE

Secteur
Coml Physical, Biologcl Resh
Industrie
Coml Physical, Biologcl Resh
Site Web
Siège social
Amsterdam, North Holland, Nld
Fondé
-
Argen X SE est coté dans le secteur Coml Physical, Biologcl Resh de la Euronext avec le ticker ARGX. Le dernier cours de clôture d'Argen X était de 599,80 €. Au cours de la dernière année, les actions de Argen X ont été négociées dans une fourchette de prix de 271,00 € à 613,00 €.

Argen X compte actuellement 59 194 000 actions en circulation. La capitalisation boursière d'Argen X est de 35,50 € milliard. Argen X a un ratio cours/bénéfice (ratio PE) de -121.30.

ARGX Dernières nouvelles

argenx to Present at Upcoming Investor Conferences

November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for...

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

First and only NMPA-approved treatment for patients with CIDP in China  Second VYVGART Hytrulo indication approved in China  November 11, 2024 – 7:30am ET  Amsterdam, the Netherlands— argenx...

argenx to Participate at Upcoming Investor Conferences

November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference...

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability...

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced...

argenx to Present at Upcoming Investor Conferences

August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin four additional registrational...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
123.64.06196213425581613577.462076599.54503963DE
433.65.88441330998571613569.661368589.97939387DE
12129.927.3646513588474.7613467.658304546.24457958DE
26251.471.1778029445353.2613352.963420488.46246358DE
52321.6113.63957597228361327162234420.51209553DE
156285.489.4110275689319.2613224.165339376.08755572DE
260455.1304.414715719149.561393.0574489297.94845287DE

ARGX - Frequently Asked Questions (FAQ)

What is the current Argen X share price?
The current share price of Argen X is 604,60 €
How many Argen X shares are in issue?
Argen X has 59 194 000 shares in issue
What is the market cap of Argen X?
The market capitalisation of Argen X is EUR 35,5B
What is the 1 year trading range for Argen X share price?
Argen X has traded in the range of 271,00 € to 613,00 € during the past year
What is the PE ratio of Argen X?
The price to earnings ratio of Argen X is -121,3
What is the cash to sales ratio of Argen X?
The cash to sales ratio of Argen X is 28,21
What is the reporting currency for Argen X?
Argen X reports financial results in USD
What is the latest annual turnover for Argen X?
The latest annual turnover of Argen X is USD 1,27B
What is the latest annual profit for Argen X?
The latest annual profit of Argen X is USD -295,05M
What is the registered address of Argen X?
The registered address for Argen X is LAARDERHOOGTWEG 25, AMSTERDAM, NORTH HOLLAND, 1101 EB
What is the Argen X website address?
The website address for Argen X is www.argenx.com
Which industry sector does Argen X operate in?
Argen X operates in the COML PHYSICAL, BIOLOGCL RESH sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
TMBSZTME Pharma NV
0,02 €
(185,71%)
132,5k
MLGEQGentlemen S Equity SA
0,0175 €
(118,75%)
1,14k
ALCYBCybergun
0,0002 €
(100,00%)
17,54M
MLAAHAmatheon Agri Holding NV
0,0185 €
(54,17%)
40,1k
ALARFAdeunis
0,94 €
(28,77%)
5,27k
MLSMLSmalto
0,0125 €
(-37,50%)
2,34k
MLFTIFrance Tourisme Immobilier
0,025 €
(-35,90%)
56,77k
CNVCnova NV
0,209 €
(-19,62%)
26,38k
MLWEAWeaccess Group
0,382 €
(-16,96%)
5,95k
ALEUPEuroplasma
0,0353 €
(-15,95%)
3,16M
ATOAtos SE
0,0021 €
(0,00%)
2,71B
BCPBanco Comercial Portugues SA
0,4493 €
(-0,69%)
66,54M
ALHGLouis Hachette Group
1,3342 €
(4,87%)
52,04M
KPNKoninklijke KPN NV
3,509 €
(-1,21%)
26,9M
VIVVivendi SE
2,51 €
(2,41%)
26,39M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock